Limits...
Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.

Sato A, Nakamura N, Kojima M, Ohmachi K, Carreras J, Kikuti YY, Numata H, Ohgiya D, Tazume K, Amaki J, Moriuchi M, Miyamoto M, Aoyama Y, Kawai H, Ichiki A, Hara R, Kawada H, Ogawa Y, Ando K - Cancer Sci. (2014)

Bottom Line: The incidence of Epstein-Barr virus (EBV)-positive DLBCL in Asian and Latin American countries ranges from 8 to 10%.The presence of EBV in lymphoma cells was detected using EBV-encoded RNA in situ hybridization, and it was found that 18 (6.9%) of 260 patients with diagnosed DLBCL tested positive.The outcome of patients with EBV-positive DLBCL remains poor, even in the rituximab era.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology-Oncology, School of Medicine, Tokai University, Isehara, Japan.

Show MeSH

Related in: MedlinePlus

Overall survival (OS) in immunocompetent Epstein–Barr virus (EBV)-positive versus EBV-negative patients with diffuse large B-cell lymphoma. The median OS in EBV-positive patients was 8.7 months; OS could not be determined in EBV-negative patients. Hazard ratio = 3.9; 95% confidence interval, 4.0–49.3; P < 0.0001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4462402&req=5

fig01: Overall survival (OS) in immunocompetent Epstein–Barr virus (EBV)-positive versus EBV-negative patients with diffuse large B-cell lymphoma. The median OS in EBV-positive patients was 8.7 months; OS could not be determined in EBV-negative patients. Hazard ratio = 3.9; 95% confidence interval, 4.0–49.3; P < 0.0001.

Mentions: The median follow-up time of surviving patients was 25.2 months (range, 0.8–71.3 months). Median OS was 8.7 months in EBV-positive patients and was not reached in EBV-negative patients (P < 0.0001; Fig.1). Three EBV-positive patients could not receive chemotherapy because their general condition was poor and disease progression was rapid.


Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.

Sato A, Nakamura N, Kojima M, Ohmachi K, Carreras J, Kikuti YY, Numata H, Ohgiya D, Tazume K, Amaki J, Moriuchi M, Miyamoto M, Aoyama Y, Kawai H, Ichiki A, Hara R, Kawada H, Ogawa Y, Ando K - Cancer Sci. (2014)

Overall survival (OS) in immunocompetent Epstein–Barr virus (EBV)-positive versus EBV-negative patients with diffuse large B-cell lymphoma. The median OS in EBV-positive patients was 8.7 months; OS could not be determined in EBV-negative patients. Hazard ratio = 3.9; 95% confidence interval, 4.0–49.3; P < 0.0001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4462402&req=5

fig01: Overall survival (OS) in immunocompetent Epstein–Barr virus (EBV)-positive versus EBV-negative patients with diffuse large B-cell lymphoma. The median OS in EBV-positive patients was 8.7 months; OS could not be determined in EBV-negative patients. Hazard ratio = 3.9; 95% confidence interval, 4.0–49.3; P < 0.0001.
Mentions: The median follow-up time of surviving patients was 25.2 months (range, 0.8–71.3 months). Median OS was 8.7 months in EBV-positive patients and was not reached in EBV-negative patients (P < 0.0001; Fig.1). Three EBV-positive patients could not receive chemotherapy because their general condition was poor and disease progression was rapid.

Bottom Line: The incidence of Epstein-Barr virus (EBV)-positive DLBCL in Asian and Latin American countries ranges from 8 to 10%.The presence of EBV in lymphoma cells was detected using EBV-encoded RNA in situ hybridization, and it was found that 18 (6.9%) of 260 patients with diagnosed DLBCL tested positive.The outcome of patients with EBV-positive DLBCL remains poor, even in the rituximab era.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology-Oncology, School of Medicine, Tokai University, Isehara, Japan.

Show MeSH
Related in: MedlinePlus